Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (325)	1/14/1999 8:40:00 PM
From: wolfdog2	Read Replies (2) \| Respond to of 712

George, I learned the hard way that getting FDA approval and marketing the drug are two very different things. I have two other biotechs in my portfolio that have approved drugs and snail slow acceptance by the medical community. Physicians are very slow to change their practices. So it takes time and education. I think that Integrelin is doing very well for a new drug, especially considering that it's battling against two other drugs which are approved for at least some of the same indications. What bothered me about the Eisinger piece was his damning the ramp-up, when in fact it, at least in my opinion, has been going very well. Many Wall St analysts also seem to fail to understand the difficulties of introducing a new drug. Hence, in buying biotechs based on analysts' estimates of future revenues, one needs to take them with a barrel of salt.